FDA Panel Supports HeartWare VAD, Despite Trial Shortcomings
This article was originally published in The Gray Sheet
Benefits of HeartWare system, as well as the prospect of adding a competitive device to a market currently dominated by a single product, overshadow uncertainties from missing data, panelists vote.
You may also be interested in...
HeartWare International Inc.’s HeartWare Ventricular Assist System has finally gained PMA approval, but FDA labeling requirements have sparked questions from analysts.
Recent launches and approvals include the HeartWare ventricular assist system, Roche’s Elecsys HE4 assay for ovarian cancer and Coloplast’s Altis single-incision sling system.
CMS does not currently have a national coverage determination process open on ventricular assist devices for heart failure, though the agency may open a new one, an agency official said.